Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 14/20 | 0.80 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.66 |
| ▸ | PIM1 | P11309 | 4/20 | 0.66 |
| ▸ | PRKACA | P17612 | 4/20 | 0.66 |
| ▸ | GSK3A | P49840 | 4/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.66 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.66 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.66 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.60 |
| ▸ | GSK3B | P49841 | 3/20 | 0.60 |
| ▸ | CHUK | O15111 | 2/20 | 0.60 |
| ▸ | AKT2 | P31751 | 2/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.60 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.60 |
| ▸ | CLK2 | P49760 | 2/20 | 0.60 |
| ▸ | PRKX | P51817 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6833772 | 1.00 | AKT1 (0.80) | AKT1ROCK2ROCK1PIM1PRKACA | |
| Hydrochloric Acid SCHEMBL7069058 | 0.88 | AKT1 (0.98) | AKT1ROCK2ROCK1PIM1PRKACA | |
| Hydrochloric Acid SCHEMBL6833647 | 0.88 | AKT1 (0.98) | AKT1ROCK2ROCK1PIM1PRKACA | |
| Hydrochloric Acid SCHEMBL6833648 | 0.88 | AKT1 (0.98) | AKT1ROCK2ROCK1PIM1PRKACA | |
| SCHEMBL6853310 | 0.85 | AKT1 (0.65) | AKT1ROCK2ROCK1PIM1PRKACA | |
| SCHEMBL6853302 | 0.85 | AKT1 (0.65) | AKT1ROCK2ROCK1PIM1PRKACA | |
| SCHEMBL6853308 | 0.85 | AKT1 (0.65) | AKT1ROCK2ROCK1PIM1PRKACA | |
| Hydrochloric Acid SCHEMBL6853378 | 0.79 | AKT1 (0.98) | AKT1ROCK2ROCK1PIM1PRKACA | |
| SCHEMBL27744399 | 0.77 | AAK1 (0.61) | AKT1ROCK2ROCK1 | |
| SCHEMBL4533616 | 0.77 | AAK1 (0.61) | AKT1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | claimed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | claimed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | claimed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | claimed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885ROCK2 581/4885ROCK1 446/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885ROCK2 581/4885ROCK1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.